Galena Biopharma Inc. (GALE) Lifted to Buy at Zacks Investment Research


The brokerage presently has a $0.25 price target on the biotechnology company's stock. Zacks Investment Research's price objective points to a potential upside of 33.83% from the company's current price.



from Biotech News